Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- As Japan Goes Digital on Package Inserts, Distributors Fret Proposed Paper-Based Rule on “1st Delivery”
February 18, 2019
- Crysvita Shows Long-Term Benefits in Pediatric XLH Study
February 18, 2019
- Shire’s Product Sales Up 3.9% in 2018: Takeda
February 18, 2019
- Asahi Kasei Pharma Sets Up New Firm for Teribone Authorized Generic
February 18, 2019
- Toa, Nipro, Nihon Generic Codeveloped Symbicort Copies, Launch Timing Unclear
February 18, 2019
- Merck Serono Japan to Be Renamed “Merck Biopharma” in April
February 18, 2019
- Rexulti Misses Primary Goal in Global PIII for Bipolar I Disorder: Otsuka, Lundbeck
February 18, 2019
- Ohara Licenses Novel Glioma Treatment from US Pharma Aiming to Bolster Pediatric Pipelines
February 18, 2019
- Mitsubishi Tanabe to Begin Clinical Study in US for c-Met Targeting ADC
February 15, 2019
- Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue
February 15, 2019
- Kowa to Reshuffle Pharma Business in April, Launching New Company for LLP Operations
February 15, 2019
- Armed with Positive Data, G47Δ Could Reach Filing in May as Japan’s 1st Oncolytic Virus
February 14, 2019
- Recordati Ratcheting Up Japan Biz, Set to Enrich Rare Disease Portfolio
February 14, 2019
- Upbeat Global Brands Drive Otsuka Sales in 2018
February 14, 2019
- GSK Japan’s Fauchet Bows Out as Chairman
February 14, 2019
- Avanir, DOJ Reach Agreement over Nuedexta Marketing Activity Case
February 14, 2019
- Eisai Files Fycompa in Europe for Pediatric Use
February 14, 2019
- MSD Files Keytruda/Inlyta Combo in Japan as 1st-Line Therapy for RCC
February 14, 2019
- Generic Player Ohara Looks to Morph into Innovative Drug Maker, with Focus on Oncology
February 13, 2019
- Takeda’s Adcetris Gets European OK for 1st-Line Stage IV Hodgkin’s Lymphoma
February 13, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…